Teva’s IGALMI receives FDA approval for at-home treatment of acute agitation in schizophrenia and bipolar disorder, supported by Phase 3 SERENITY findings.
Written By: Saniya Katakdhond, PharmD
Reviewed By: Pharmacally Editorial Team
On November 16, 2026, the U.S. Food and Drug Administration (FDA) approved Teva Pharmaceuticals’ supplemental New Drug Application (sNDA) for IGALMI (dexmedetomidine) sublingual film for at-home self-administration in adults experiencing acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. The decision makes IGALMI the first FDA-approved treatment specifically indicated for patient self-administration at home during acute agitation episodes associated with these conditions.
Agitation is a disruptive clinical symptom characterized by internal tension, restlessness, and heightened motor or verbal activity. According to Teva, it affects approximately 25%–40% of individuals with these psychiatric conditions. Episodes can escalate rapidly, with up to 21% requiring emergency medical attention or hospitalization. Before this approval, no FDA-approved pharmacotherapy carried a specific indication for self-administration at home during acute agitation episodes.
Phase 3 SERENITY At-Home Trial: Safety and Tolerability Findings
The approval was supported by the Phase 3 SERENITY At-Home Safety and Tolerability Trial (NCT05658510), a 12-week, randomized, double-blind, placebo-controlled study evaluating as-needed self-administration of sublingual dexmedetomidine (120 mcg) outside supervised healthcare settings.
The trial randomized 246 patients, of whom 208 received study treatment across 2,437 agitation episodes. In the active-treatment arm, 102 patients received IGALMI across 1,160 episodes, while 106 patients received placebo across 1,277 episodes.
The study met its primary safety and tolerability objective, which included assessment of serious adverse events and treatment-emergent adverse events following dosing. Repeat-dose analyses showed no increasing trend in adverse-event frequency over the 12-week observation period. No patients in the IGALMI group discontinued treatment because of treatment-emergent adverse events.
The most frequently reported adverse events, occurring at an incidence of at least 5% and greater than placebo, included somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia. These findings were consistent with dexmedetomidine’s known pharmacological profile. Importantly, the study primarily evaluated repeat-dose safety and tolerability rather than establishing a separate efficacy claim for at-home treatment.
Earlier SERENITY Trials Established Efficacy in Supervised Settings
IGALMI contains dexmedetomidine, a selective alpha-2 adrenergic receptor agonist formulated as a sublingual film. It is administered under the tongue or between the lower lip and gum.
Its efficacy for acute agitation was established through the Phase 3 SERENITY I and SERENITY II trials, conducted in healthcare-supervised settings in patients with schizophrenia and bipolar I or II disorder, respectively.
These randomized, double-blind, placebo-controlled studies demonstrated statistically significant reductions in agitation, measured using the Positive and Negative Syndrome Scale-Excited Component (PEC) total score. Across the studies, IGALMI produced an average reduction of approximately 9.6 points at two hours after administration, compared with approximately 4.9 points with placebo. Treatment effects were observed as early as 20 minutes after some doses.
The distinction between efficacy established in supervised settings and safety and tolerability evaluated during at-home administration remains important when interpreting the expanded indication.
Safety Considerations for At-Home Administration
At-home use requires appropriate patient selection and attention to dexmedetomidine’s cardiovascular and central nervous system effects. Prescribing information identifies hypotension, orthostatic hypotension, and bradycardia as potentially serious adverse effects. QT interval prolongation is another important consideration.
Clinicians should assess cardiovascular history, previous syncope, hypovolemia, electrolyte abnormalities, diabetes, hepatic impairment, and concomitant medications, particularly those that lower blood pressure, cause sedation, or prolong the QT interval.
Patients should maintain adequate hydration, sit or lie down after administration, and rise slowly to reduce the risk of fainting and falls. Because somnolence can impair alertness, patients should avoid driving and operating hazardous machinery for at least eight hours after administration. Concomitant use with sedatives, hypnotics, anaesthetics, or opioids may increase central nervous system depression.
These precautions reinforce the importance of medical guidance and appropriate patient and caregiver education during at-home treatment.
BioXcel Development History and Teva Commercialization Plans
BioXcel Therapeutics originally developed the SERENITY clinical programme and submitted the sNDA to the FDA on January 14, 2026. Teva subsequently completed the acquisition of worldwide rights to IGALMI and BXCL501 on October 27, 2026, through a court-supervised Section 363 asset sale.
Following the acquisition, Teva assumed responsibility for the product and its commercialization. The company stated that plans for introducing the at-home indication would be announced at a later date.
Clinical Interpretation
The FDA approval expands the treatment setting for IGALMI by allowing patient self-administration outside healthcare-supervised environments. Its clinical significance rests on extending an established treatment option to acute agitation episodes that may occur at home or in community settings.
The absence of treatment-emergent adverse event-related discontinuations among 102 IGALMI-treated patients and the experience across 1,160 treatment episodes support the tolerability of repeated administration over the 12-week study period. However, these findings should not be interpreted as evidence of independently established at-home efficacy or long-term safety.
Clinical adoption will depend on appropriate patient selection, awareness of cardiovascular and sedative risks, and clear instructions for administration and escalation of care when agitation persists.
Reference
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults, Teva Pharmaceuticals, 16 November 2026
Dexmedetomidine in the Treatment of Agitation Associated with Schizophrenia and Bipolar Disorder (SERENITY III), ClinicalTrials.gov ID NCT05658510
About the Writer
Saniya Sanjay Katakdhond (Linkedin) is a Doctor of Pharmacy professional with hands-on experience in patient case review, clinical documentation, medical record analysis, and patient care.
Her hospital experience has strengthened her understanding of clinical conditions, treatment approaches, and multidisciplinary healthcare practices.
With ICH-GCP certification and a research-oriented approach, she brings clinical insight and attention to detail to healthcare content development.
As a healthcare writer, Saniya focuses on translating clinical knowledge and patient-care experience into clear, accurate, and evidence-informed medical content.
